RPRX
Royalty Pharma Plc
58.40$
+0.1%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +22,941.0% | -3.1% | +8.5% | 0.0% | +9.5% | +69.5% | -17.0% | -4.0% | -2.6% | +11.2% | +7.7% | |
| – | +6,389.0% | -1.3% | -1.9% | -11.5% | -68.1% | +224.1% | +6.7% | -11.2% | -50.1% | +41.4% | -65.7% | |
| – | +3,591.3% | -2.7% | -17.5% | +39.3% | -87.2% | +309.8% | +52.7% | +11.0% | -72.1% | +94.8% | -33.4% | |
| – | – | -2.7% | -17.5% | +72.7% | -66.8% | +151.1% | +40.7% | -13.4% | -49.2% | +43.5% | -64.0% | |
| – | – | – | – | – | -80.5% | +1.0% | +74.4% | -46.4% | -38.8% | +20.3% | +3,178.3% | |
| – | – | – | – | – | – | – | -100.0% | +0.0% | – | – | – | |
| – | -75.0% | -62.5% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -31.6% | -44.6% | -80.2% | +155.7% | -87.7% | +850,696.3% | – | |
| – | +209,153.8% | -1.6% | +14.7% | -1.2% | -7.5% | -2.9% | +18.7% | +0.3% | -13.6% | +25.1% | +25.7% | |
| – | +10,652.1% | -5.4% | +29.0% | +51.3% | -42.5% | -7.7% | -44.4% | +581.3% | -86.2% | +676.8% | -49.2% | |
| – | – | -6.3% | +62.7% | +0.2% | +0.2% | +0.0% | +2,344.0% | -85.5% | – | – | -61.9% | |
| – | -5.8% | -4.5% | – | – | +149.7% | -3.6% | -47.8% | +40.7% | +91.8% | -11.8% | +45.1% | |
| – | – | – | – | – | -4.5% | -2.3% | +22.0% | -13.8% | +0.3% | +7.8% | +29.6% | |
| – | +10,525.2% | -4.9% | +0.3% | +0.6% | +36.0% | +145.2% | -31.6% | -45.1% | +16.0% | +6.4% | -6.8% | |
| – | – | – | – | – | +132.3% | -32.0% | +17.4% | -12.9% | +28.1% | +13.0% | -17.2% | |
| – | +71.4% | +0.0% | -41.7% | +0.0% | +0.0% | +6.0% | +10.5% | +36.2% | +6.7% | -1.5% | -5.8% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.